alprazolam has been researched along with As If Personality in 15 studies
Alprazolam: A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238)
alprazolam : A member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In 123 panic disorder patients undergoing gradual tapered discontinuation of alprazolam in conjunction with pre-treatment with carbamazepine or placebo, the relationship between measures of 'symptom sensitivity' and 'harm avoidance', and severity of withdrawal symptoms measured as peak severity of symptoms, time before taper needed to be slowed due to symptoms, and ability to complete taper, was examined." | 9.10 | Personality and symptom sensitivity predictors of alprazolam withdrawal in panic disorder. ( Ballenger, J; Bell, J; Bystrisky, A; Corrigan, MH; Pollack, M; Rosenbaum, J; Roy-Byrne, P; Rush, AJ; Russo, J; Stewart, R; Stolk, J, 2003) |
| "Sixteen female outpatients with borderline personality disorder and prominent behavioral dyscontrol, but without a current episode of major depression, were studied in a double-blind, crossover trial of placebo and the following four active medications: alprazolam (average dose, 4." | 9.06 | Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. ( Cowdry, RW; Gardner, DL, 1988) |
| "The authors report a significant increase in dyscontrol in patients with borderline personality disorder who were taking alprazolam during a double-blind, placebo-controlled crossover study." | 9.05 | Alprazolam-induced dyscontrol in borderline personality disorder. ( Cowdry, RW; Gardner, DL, 1985) |
| "Three patients who met DSM-III criteria for borderline personality disorder and who did not improve while taking a number of other drugs improved substantially while taking alprazolam." | 7.67 | The positive effect of alprazolam in the treatment of three patients with borderline personality disorder. ( Faltus, FJ, 1984) |
| " They are mostly presented in the group of mood stabilizers and antiepileptic drugs, particularly the carbamazepine and lamotrigine, and can be manifested through the Stevens Johnson syndrome, Toxic Epidermal Necrolysis (TEN)/Lyell's syndrome with about 30% lethality." | 5.37 | Exanthema medicamentosum as a side effect of promazine. ( Cvitanović, MZ; Hlevnjak, I; Lasić, D; Uglešić, B; Višić, V, 2011) |
| "In 123 panic disorder patients undergoing gradual tapered discontinuation of alprazolam in conjunction with pre-treatment with carbamazepine or placebo, the relationship between measures of 'symptom sensitivity' and 'harm avoidance', and severity of withdrawal symptoms measured as peak severity of symptoms, time before taper needed to be slowed due to symptoms, and ability to complete taper, was examined." | 5.10 | Personality and symptom sensitivity predictors of alprazolam withdrawal in panic disorder. ( Ballenger, J; Bell, J; Bystrisky, A; Corrigan, MH; Pollack, M; Rosenbaum, J; Roy-Byrne, P; Rush, AJ; Russo, J; Stewart, R; Stolk, J, 2003) |
| "In a double-blind, placebo-controlled study, the efficacy and safety of alprazolam was investigated in childhood and adolescent anxiety disorders." | 5.07 | Clinical, cognitive, and neurophysiological effects of alprazolam in children and adolescents with overanxious and avoidant disorders. ( Dubois, C; Ferguson, HB; Gauthier, B; Knott, V; Roberts, N; Simeon, JG; Wiggins, D, 1992) |
| "Sixteen female outpatients with borderline personality disorder and prominent behavioral dyscontrol, but without a current episode of major depression, were studied in a double-blind, crossover trial of placebo and the following four active medications: alprazolam (average dose, 4." | 5.06 | Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. ( Cowdry, RW; Gardner, DL, 1988) |
| "The authors report a significant increase in dyscontrol in patients with borderline personality disorder who were taking alprazolam during a double-blind, placebo-controlled crossover study." | 5.05 | Alprazolam-induced dyscontrol in borderline personality disorder. ( Cowdry, RW; Gardner, DL, 1985) |
| "Three patients who met DSM-III criteria for borderline personality disorder and who did not improve while taking a number of other drugs improved substantially while taking alprazolam." | 3.67 | The positive effect of alprazolam in the treatment of three patients with borderline personality disorder. ( Faltus, FJ, 1984) |
| " They are mostly presented in the group of mood stabilizers and antiepileptic drugs, particularly the carbamazepine and lamotrigine, and can be manifested through the Stevens Johnson syndrome, Toxic Epidermal Necrolysis (TEN)/Lyell's syndrome with about 30% lethality." | 1.37 | Exanthema medicamentosum as a side effect of promazine. ( Cvitanović, MZ; Hlevnjak, I; Lasić, D; Uglešić, B; Višić, V, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (46.67) | 18.7374 |
| 1990's | 5 (33.33) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 1 (6.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lasić, D | 1 |
| Cvitanović, MZ | 1 |
| Uglešić, B | 1 |
| Višić, V | 1 |
| Hlevnjak, I | 1 |
| Roy-Byrne, P | 1 |
| Russo, J | 1 |
| Pollack, M | 1 |
| Stewart, R | 1 |
| Bystrisky, A | 1 |
| Bell, J | 1 |
| Rosenbaum, J | 1 |
| Corrigan, MH | 1 |
| Stolk, J | 1 |
| Rush, AJ | 1 |
| Ballenger, J | 1 |
| Prasko, J | 1 |
| Houbová, P | 1 |
| Novák, T | 1 |
| Záleský, R | 1 |
| Espa-Cervená, K | 1 |
| Pasková, B | 1 |
| Vyskocilová, J | 1 |
| Faltus, FJ | 1 |
| Jordan, J | 1 |
| Starcevic, V | 1 |
| Uhlenhuth, EH | 1 |
| Simeon, JG | 1 |
| Ferguson, HB | 1 |
| Knott, V | 1 |
| Roberts, N | 1 |
| Gauthier, B | 1 |
| Dubois, C | 1 |
| Wiggins, D | 1 |
| Sheehan, MF | 1 |
| Sheehan, DV | 1 |
| Torres, A | 1 |
| Coppola, A | 1 |
| Francis, E | 1 |
| Pollack, MH | 1 |
| Otto, MW | 1 |
| Rosenbaum, JF | 1 |
| Sachs, GS | 1 |
| O'Neil, C | 1 |
| Asher, R | 1 |
| Meltzer-Brody, S | 1 |
| Rajadhyaksha, S | 1 |
| Gardner, DL | 3 |
| Cowdry, RW | 3 |
| Reich, J | 2 |
| Noyes, R | 1 |
| Yates, W | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Role of Orexin in Human Panic Disorder[NCT02593682] | Phase 4 | 3 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for alprazolam and As If Personality
| Article | Year |
|---|---|
Suicidal and parasuicidal behavior in borderline personality disorder.
Topics: Adolescent; Adult; Alprazolam; Benzodiazepines; Borderline Personality Disorder; Carbamazepine; Diss | 1985 |
6 trials available for alprazolam and As If Personality
| Article | Year |
|---|---|
Personality and symptom sensitivity predictors of alprazolam withdrawal in panic disorder.
Topics: Adult; Alprazolam; Anti-Anxiety Agents; Dose-Response Relationship, Drug; Female; Humans; Male; Pani | 2003 |
Influence of personality disorder on the treatment of panic disorder--comparison study.
Topics: Adult; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Cognitive Behavioral Therapy; Combined Modality | 2005 |
Clinical, cognitive, and neurophysiological effects of alprazolam in children and adolescents with overanxious and avoidant disorders.
Topics: Adolescent; Alprazolam; Anxiety Disorders; Arousal; Cerebral Cortex; Child; Double-Blind Method; Ele | 1992 |
Alprazolam-induced dyscontrol in borderline personality disorder.
Topics: Adult; Alprazolam; Ambulatory Care; Anti-Anxiety Agents; Benzodiazepines; Borderline Personality Dis | 1985 |
Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine.
Topics: Adult; Alprazolam; Ambulatory Care; Borderline Personality Disorder; Carbamazepine; Clinical Trials | 1988 |
A pilot study of treatment of social phobia with alprazolam.
Topics: Adult; Aged; Alprazolam; Clinical Trials as Topic; Drug Administration Schedule; Female; Humans; Mal | 1988 |
8 other studies available for alprazolam and As If Personality
| Article | Year |
|---|---|
Exanthema medicamentosum as a side effect of promazine.
Topics: Adult; Alprazolam; Anti-Allergic Agents; Anti-Anxiety Agents; Anti-Bacterial Agents; Anti-Inflammato | 2011 |
The positive effect of alprazolam in the treatment of three patients with borderline personality disorder.
Topics: Adult; Alprazolam; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Borderline Personalit | 1984 |
Use of a revised version of the psychotropic medication efficacy graph.
Topics: Adult; Alprazolam; Haloperidol; Humans; Intellectual Disability; Male; Neurocognitive Disorders; Per | 1994 |
Personality dimensions in panic disorder before and after effective treatment.
Topics: Adult; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Female; Humans; Male; Middle Aged; Panic Disord | 1996 |
Snorting benzodiazepines.
Topics: Administration, Intranasal; Adult; Alprazolam; Anti-Anxiety Agents; Arousal; Bipolar Disorder; Diaze | 1991 |
Longitudinal course of panic disorder: findings from the Massachusetts General Hospital Naturalistic Study.
Topics: Alprazolam; Anxiety Disorders; Child, Preschool; Chronic Disease; Clonazepam; Cognitive Behavioral T | 1990 |
Avoidant personality traits in social phobic patients treated with alprazolam.
Topics: Alprazolam; Humans; Personality Disorders; Phobic Disorders; Psychotherapy | 1989 |
Alprazolam treatment of avoidant personality traits in social phobic patients.
Topics: Adult; Alprazolam; Anxiety Disorders; Female; Humans; Male; Panic; Personality Disorders; Phobic Dis | 1989 |